X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs GLENMARK PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD GLENMARK PHARMA ORCHID PHARMA LTD/
GLENMARK PHARMA
 
P/E (TTM) x -0.5 12.0 - View Chart
P/BV x 0.4 3.2 11.5% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ORCHID PHARMA LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
GLENMARK PHARMA
Mar-17
ORCHID PHARMA LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs194993 19.5%   
Low Rs35729 4.8%   
Sales per share (Unadj.) Rs276.5325.5 84.9%  
Earnings per share (Unadj.) Rs-79.239.3 -201.6%  
Cash flow per share (Unadj.) Rs-43.548.7 -89.3%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs53.9159.2 33.9%  
Shares outstanding (eoy) m70.45282.17 25.0%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x0.42.6 15.7%   
Avg P/E ratio x-1.421.9 -6.6%  
P/CF ratio (eoy) x-2.617.7 -14.9%  
Price / Book Value ratio x2.15.4 39.2%  
Dividend payout %05.1 0.0%   
Avg Mkt Cap Rs m8,067242,991 3.3%   
No. of employees `0002.813.0 21.6%   
Total wages/salary Rs m2,52716,408 15.4%   
Avg. sales/employee Rs Th6,956.17,083.9 98.2%   
Avg. wages/employee Rs Th902.51,265.4 71.3%   
Avg. net profit/employee Rs Th-1,993.0855.1 -233.1%   
INCOME DATA
Net Sales Rs m19,47791,857 21.2%  
Other income Rs m407374 109.0%   
Total revenues Rs m19,88492,230 21.6%   
Gross profit Rs m1,10320,367 5.4%  
Depreciation Rs m2,5192,644 95.3%   
Interest Rs m5,2272,373 220.2%   
Profit before tax Rs m-6,23615,724 -39.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-810 -63.1%   
Tax Rs m-1253,827 -3.3%   
Profit after tax Rs m-5,58011,088 -50.3%  
Gross profit margin %5.722.2 25.5%  
Effective tax rate %2.024.3 8.2%   
Net profit margin %-28.712.1 -237.4%  
BALANCE SHEET DATA
Current assets Rs m11,01468,746 16.0%   
Current liabilities Rs m32,06027,027 118.6%   
Net working cap to sales %-108.145.4 -237.9%  
Current ratio x0.32.5 13.5%  
Inventory Days Days9585 111.6%  
Debtors Days Days3496 35.1%  
Net fixed assets Rs m29,44024,132 122.0%   
Share capital Rs m705282 249.6%   
"Free" reserves Rs m2,04344,643 4.6%   
Net worth Rs m3,80044,925 8.5%   
Long term debt Rs m9,01845,363 19.9%   
Total assets Rs m46,510117,639 39.5%  
Interest coverage x-0.27.6 -2.5%   
Debt to equity ratio x2.41.0 235.0%  
Sales to assets ratio x0.40.8 53.6%   
Return on assets %-0.811.4 -6.6%  
Return on equity %-146.924.7 -595.0%  
Return on capital %-3.719.1 -19.5%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51356,152 13.4%   
Fx outflow Rs m5,6498,084 69.9%   
Net fx Rs m1,86548,068 3.9%   
CASH FLOW
From Operations Rs m1,6826,574 25.6%  
From Investments Rs m-9,860-7,124 138.4%  
From Financial Activity Rs m6,6445,432 122.3%  
Net Cashflow Rs m-1,5351,992 -77.0%  

Share Holding

Indian Promoters % 32.3 48.3 66.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 6.9 66.7%  
FIIs % 3.3 34.4 9.6%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.5 526.7%  
Shareholders   84,811 56,727 149.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of PNB Fraud, Rising Troubles at PSBs, and Top Cues in Focus Today(Pre-Open)

Share markets in India closed on a negative note yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 236 points and the NSE Nifty closed down by 74 points.

Related Views on News

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Feb 19, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS